National Survey on Gastroesophageal Reflux Disease (GERD) Patients - Full Text View

National Survey on Gastroesophageal Reflux Disease (GERD) Patients (LINEA)

This study has been completed.

First Received: June 10, 2008 Last Updated: August 4, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00695838

Purpose

The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms .

Condition
GERD

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice

Resource links provided by NLM:

MedlinePlus related topics: GERD

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Secondary Outcome Measures:

Biospecimen Retention: None Retained

Biospecimen Description:

Groups/Cohorts
1

Eligibility

Study Population

First three consecutive patients with GERD symptoms seen by GP

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695838

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Alain Castaigne, Medical Director

AstraZeneca

More Information

No publications provided

Responsible Party:	AstraZeneca Pharmaceuticals ( Alain Castaigne, Medical Director )
Study ID Numbers:	NIS-GFR-DUM-2007/3
Study First Received:	June 10, 2008
Last Updated:	August 4, 2009
ClinicalTrials.gov Identifier:	NCT00695838 History of Changes
Health Authority:	France: French Data Protection Authority

Keywords provided by AstraZeneca:

GERD symptoms- Waist circumference
Patients with symptomatic GERD

Additional relevant MeSH terms:

Deglutition Disorders
Esophageal Motility Disorders
Digestive System Diseases

Gastrointestinal Diseases
Esophageal Diseases
Gastroesophageal Reflux

ClinicalTrials.gov processed this record on February 08, 2010